38 / 40
Time to progression or treatment discontinuation
Tumor Responses
Drew Y et al: Presented at SGO, March 24-27 New Orleans, USA
Combination of PARPi and immunotherapy
Mediola: phase II olaparib + durvalumab in BRCAmut with TFIp > 6 m